Multicomponent-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity

dc.contributor.authorDi Pietro, O.
dc.contributor.authorVicente García, Esther
dc.contributor.authorTaylor, Martin C.
dc.contributor.authorBerenguer, Diana
dc.contributor.authorViayna, Elisabet
dc.contributor.authorLanzoni, Anna
dc.contributor.authorSola, Irene
dc.contributor.authorSayago, Helena
dc.contributor.authorRiera Lizandra, Ma. Cristina
dc.contributor.authorFisa Saladrigas, Roser
dc.contributor.authorClos, Victòria
dc.contributor.authorPérez Fernández, Belén
dc.contributor.authorKelly, John M.
dc.contributor.authorLavilla Grífols, Rodolfo
dc.contributor.authorMuñoz-Torrero López-Ibarra, Diego
dc.date.accessioned2015-12-23T16:10:36Z
dc.date.available2015-12-23T16:10:36Z
dc.date.issued2015-11-13
dc.date.updated2015-12-23T16:10:36Z
dc.description.abstractHuman African trypanosomiasis (HAT), Chagas disease and leishmaniasis, which are caused by the trypanosomatids Trypanosoma brucei, T. cruzi and Leishmania species, are among the most deadly neglected tropical diseases. The development of drugs that are active against several trypanosomatids is appealing from a clinical and economic viewpoint, and seems feasible, as these parasites share metabolic pathways and hence might be treatable by common drugs. From benzonapthyridine 1, an inhibitor of acetylcholinesterase (AChE) for which we have found a remarkable trypanocidal activity, we have designed and synthesized novel benzo[h][1,6]naphthyridines, pyrrolo[3,2-c]quinolines, azepino[3,2-c]quinolines, and pyrano[3,2-c]quinolines through 2‒4-step sequences featuring an initial multicomponent Povarov reaction as the key step. To assess the therapeutic potential of the novel compounds, we have evaluated their in vitro activity against T. brucei, T. cruzi, and L. infantum, as well as their brain permeability, which is of specific interest for the treatment of late-stage HAT. To assess their potential toxicity, we have determined their cytotoxicity against rat myoblast L6 cells and their AChE inhibitory activity. Several tricyclic heterofused quinoline derivatives were found to display an interesting multi-trypanosomatid profile, with one-digit micromolar potencies against two of these parasites and two-digit micromolar potency against the other. Pyranoquinoline 39, which displays IC50 values of 1.5 µM, 6.1 µM and 29.2 µM against T. brucei, L. infantum and T. cruzi, respectively, brain permeability, better drug-like properties (lower lipophilicity and molecular weight and higher CNS MPO desirability score) than hit 1, and the lowest AChE inhibitory activity of the series (IC50 > 30 µM), emerges as an interesting multi-trypanosomatid lead, amenable to further optimization particularly in terms of its selectivity index over mammalian cells.
dc.format.extent18 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec655024
dc.identifier.issn0223-5234
dc.identifier.pmid26479031
dc.identifier.urihttps://hdl.handle.net/2445/68589
dc.language.isoeng
dc.publisherElsevier Masson SAS
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1016/j.ejmech.2015.10.007
dc.relation.ispartofEuropean Journal of Medicinal Chemistry, 2015, vol. 105, p. 120-137
dc.relation.urihttp://dx.doi.org/10.1016/j.ejmech.2015.10.007
dc.rightscc-by (c) Hutter, Natalia et al., 2015
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationDisseny de medicaments
dc.subject.classificationSíntesi orgànica
dc.subject.classificationBarrera hematoencefàlica
dc.subject.classificationCompostos heterocíclics
dc.subject.classificationMedicina tropical
dc.subject.otherDrug design
dc.subject.otherOrganic synthesis
dc.subject.otherBlood-brain barrier
dc.subject.otherHeterocyclic compounds
dc.subject.otherTropical medicine
dc.titleMulticomponent-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
655024.pdf
Mida:
797.58 KB
Format:
Adobe Portable Document Format